Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
Pfizer
Eli Lilly and Company
Cancer Research UK
Cancer Research UK
Corcept Therapeutics
Marengo Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Stanford University
Karyopharm Therapeutics Inc
Karolinska Institutet
Mabwell (Shanghai) Bioscience Co., Ltd.
Revolution Medicines, Inc.
Advaxis, Inc.
Kaiser Permanente
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Jiangsu Cancer Institute & Hospital
University College, London
Eli Lilly and Company